Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective Outcomes of Second-Line Therapy in Acute Graft-Versus-Host Study Including ECP (POSTAGE)

NCT02151539 is registered in ClinicalTrials.gov with Vanderbilt-Ingram Cancer Center as lead sponsor.

NCT NCT02151539
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02151539 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective Outcomes of Second-Line Therapy in Acute Graft-Versus-Host Study Including ECP (POSTAGE)
Lead sponsor
Vanderbilt-Ingram Cancer Center
Phase
Observational
Overall status
Terminated
Start date
August 29, 2014
Completion date
October 11, 2018
Enrollment
19 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

graft versus host disease